TRINITY BIOTECH PLC
TRIB · XNASCIK 888721fmd_0737MVB22K1Q9NYM68F5YQ8CHRManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 17 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 100 | 100 | 99 | 97 | 90 | 102 | 81 | 63 | 57 | 62 |
| Cost of revenue | 54 | 56 | 57 | 56 | 52 | 53 | 48 | 45 | 37 | 40 |
| Gross profit | 47 | 43 | 42 | 41 | 38 | 49 | 33 | 17 | 19 | 21 |
| Research and development | 5 | 5 | 6 | 5 | 5 | 5 | 4 | 4 | 4 | 5 |
| Selling, general and administrative | 28 | 30 | 32 | 29 | 28 | 26 | 23 | 27 | 31 | 29 |
| Operating income | 14 | (40) | (38) | (20) | (24) | 0 | 4 | (19) | (27) | (21) |
| Interest expense | 4 | 5 | 5 | 5 | 7 | 7 | 7 | 25 | 11 | 10 |
| Income before taxes | 23 | (42) | (40) | (23) | (30) | (7) | (2) | (44) | (37) | (31) |
| Income tax expense | 1 | (4) | (1) | (1) | (1) | (1) | (0) | (0) | (0) | 0 |
| Net income from continuing operations | 22 | (39) | (39) | (23) | (29) | (6) | (2) | (44) | (37) | (31) |
| Net income | 22 | (101) | (40) | (22) | (29) | (6) | 1 | (41) | (24) | (32) |